Combine this with a large increase in funding, and you could start to see the rewards of leading a UK biotech company to success start to become enticing – the $354 million that David Hung ...

Drug development is coming back in vogue and this fund’s ‘full life cycle’ approach means it’s ready to capture the gains ...

Cell programming biotech bit.bio is slimming its workforce by 25% as the company pivots to focus on biomedical tools instead of therapeutics development. The decision was driven by “shifting ...

AstraZeneca has struck a deal to acquire biotechnology company EsoBiotec for up to $1bn ... Its investors include 4Bio Capital, a UK venture fund that backs advanced treatments such as cell ...

RoukenBio is a biotechnology company based at Braidhurst Industrial ... University of the West of Scotland (UWS), through Innovate UK’s Knowledge Transfer Partnership (KTP) scheme.

Infinitopes is a highly innovative company with a strong commitment to ... played a significant role in the upscaling from a small biotech to 500+ employees, driving innovation across discovery ...